To our knowledge, we are the first to report that osteosarcoma patients could be prognostically stratified using METTL3, YTHDC1, and FTO, which is independent of potential confounding factors including age, gender, and metastatic status. This evidence concerns the gene METTL3 and osteosarcoma.